Biosimilars could help the US Food and Drug Administration adopt cloud-based technology upgrades for clinical trial and other data analysis.
A cloud-based technology demonstration project was proposed for the biosimilar user fee program’s upcoming reauthorization, according to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?